ATOS:NSD-Atossa Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.38

Change

-0.13 (-3.70)%

Market Cap

USD 0.44B

Volume

3.98M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A

ETFs Containing ATOS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 255.79% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 255.79% 97% A+ 98% A+
Trailing 12 Months  
Capital Gain 39.67% 70% C- 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.67% 70% C- 54% F
Trailing 5 Years  
Capital Gain -87.08% 17% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.08% 17% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -12.70% 18% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.70% 18% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 58.52% 54% F 31% F
Risk Adjusted Return -21.69% 21% F 11% F
Market Capitalization 0.44B 55% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.88 62% D- 47% F
Price / Cash Flow Ratio -38.41 86% B 85% B
EV/EBITDA 0.09 77% C+ 96% A
Management Effectiveness  
Return on Equity -28.27% 79% C+ 37% F
Return on Invested Capital -88.42% 23% F 9% F
Return on Assets -14.63% 76% C 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.48 61% D- 48% F
Short Percent 19.43% 4% F 7% F
Beta 2.25 11% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.